We are international

Myeloma Minute
April 2, 2015
April 2, 2015
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF

This week's question: What are myeloma treatment options for a patient with bipolar disorder?

Multiple Myeloma Bone Study

Ixazomib in Newly Diagnosed and/or Relapsed/Refractory Myeloma

Ixazomib Citrate Maintenance Therapy After ASCT


Join the conversation about myeloma on the Smart Patients Message Board


Upcoming Events

Friday, April 10, 2015
2015 Kubik Multiple Myeloma Benefit
Rowlett, Texas


Saturday, April 11, 2015
Myeloma Center Workshop
Dallas, Texas


Saturday, April 18, 2015
2nd Annual Kristin O'Neill Memorial Cup Spaghetti Dinner & Hockey Game
Pittsburgh, Pennsylvania


Saturday, April 25, 2015
7th Annual Miles for Myeloma 5K Run/Walk
Philadelphia, Pennsylvania


Watch the IMF Mambo for Myeloma & Support This Challenge




Can Polio or Other Viruses Treat Myeloma?

IMF Chairman Dr. Brian Durie responds in his blog this week to a recent 60 Minutes segment on using the polio virus to treat cancer. Myeloma patients may wonder if this is an option for them, but as Dr. Durie explains, the polio virus needs to be contained within the shell of a solid tumor to be effective. CLICK HERE to read more about where virotherapy for myeloma might be heading.


Another Successful Myeloma Awareness Month!


The IMF’s message “Knowledge is Power” was shared far and wide last month as the key theme of Myeloma Awareness Month (#MAM). Patient advocates secured proclamations recognizing March as Myeloma Awareness Month from 28 states, cities, and counties. In addition, a Federal resolution was introduced to recognize March 2015 as “National Myeloma Awareness Month.” Read more about the many IMF-hosted #MAM events HERE.


FDA Grants Priority Review for Kyprolis® in Relapsed Patients

There was good news for myeloma patients this week as the FDA accepted the supplemental New Drug Application of Kyprolis (carfilzomib) for treatment by injection. The application applies to those with relapsed myeloma who have received at least one prior therapy. As part of the acceptance, the FDA granted Kyprolis priority review with a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2015. CLICK HERE to read more.


NEW! Ixazomib Citrate Maintenance Therapy Study Now Recruiting

Takeda Oncology is recruiting myeloma patients to participate in a phase III, placebo-controlled, double-blind study of oral ixazomib citrate maintenance therapy. The clinical trial is designed to determine the effect of ixazomib citrate maintenance on progression-free survival in newly diagnosed myeloma patients who have had a complete, very good or partial response to induction therapy followed by high-dose therapy and an autologous stem cell transplant. CLICK HERE for more information on the clinical trial.


South Dakota and West Virginia Join the Fight For Oral Parity



Governor Dennis Daugaard from South Dakota and Governor Earl Ray Tomblin from West Virginia signed SB 101 and HB 2493, respectively, earlier this week, bringing the official tally of states with oral parity laws to 37. This is a significant victory for patients and their families and will ensure that thousands will now have access to the oral anticancer medications they need. The IMF thanks Governors Daugaard and Tomblin for their leadership on this critical issue, and we will continue to provide updates on the remaining states with active oral parity campaigns: Mississippi, New Hampshire, North Carolina, North Dakota and Pennsylvania.

Join Our Mailing List

12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF Hotline: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe

 related articles